Table 3. Pneumococcal vaccination rates with 95% CI within two years following diagnosis of immunocompromised condition.
| Cohort A: Overall | Cohort B: Overall | |||||
|---|---|---|---|---|---|---|
| N cohort | N vaccinated | Vaccination rates (95% CI) | N cohort | N vaccinated | Vaccination rates (95% CI) | |
| Overall | 193,521 | 8,401 | 4.3% (4.3%-4.4%) | 289,279 | 17,354 | 6.0% (5.9%-6.1%) |
| Females | 107,172 | 3,963 | 3.7% (3.6%-3.8%) | 156,569 | 8,148 | 5.2% (5.1%-5.3%) |
| Males | 86,349 | 4,438 | 5.1% (5.0%-5.3%) | 132,710 | 9,206 | 6.9% (6.8%-7.1%) |
| Age 2–15 | 10,225 | 72 | 0.7% (0.6%-0.9%) | 12,053 | 103 | 0.9% (0.7%-1.0%) |
| Age 16–59 | 113,955 | 2,331 | 2.0% (2.0%-2.1%) | 157,980 | 3,971 | 2.5% (2.4%-2.6%) |
| Age ≥60 | 69,341 | 5,998 | 8.7% (8.4%-8.9%) | 119,246 | 13,280 | 11.1% (11.0%-11.3%) |
| Female age 2–15 | 5,152 | 34 | 0.7% (0.5%-0.9%) | 6,140 | 43 | 0.7% (0.5%-0.9%) |
| Female age 16–59 | 68,061 | 1,105 | 1.6% (1.5%-1.7%) | 92,403 | 1,753 | 1.9% (1.8%-2.0%) |
| Female age ≥60 | 33,959 | 2,824 | 8.3% (8.0%-8.6%) | 58,026 | 6,352 | 10.9% (10.7%-11.2%) |
| Male age 2–15 | 5,073 | 38 | 0.7% (0.5%-1.0%) | 5,913 | 60 | 1.0% (0.8%-1.3%) |
| Male age 16–59 | 45,894 | 1,226 | 2.7% (2.5%-2.8%) | 65,577 | 2,218 | 3.4% (3.2%-3.5%) |
| Male age ≥60 | 35,382 | 3,174 | 9.0% (8.7%-9.3%) | 61,220 | 6,928 | 11.3% (11.1%-11.6%) |
| Immunocompromising condition | ||||||
| Functional or anatomic asplenia sickle cell diseases and other hemoglobinopathies | 1,966 | 142 | 7.2% (6.1%-8.4%) | 2,966 | 214 | 7.2% (6.3%-8.2%) |
| Other immunodeficiency | 105,977 | 3,374 | 3.2% (3.1%-3.3%) | 148,717 | 6,373 | 4.3% (4.2%-4.4%) |
| Malignant neoplasms excl. non-melanoma skin cancer | 39,619 | 1,953 | 4.9% (4.7%-5.1%) | 60,070 | 3,931 | 6.5% (6.3%-6.7%) |
| Stem cell transplantation | 10 | <5* | *- | 18 | <5* | *- |
| HIV infection | 832 | 88 | 10.6% (8.6%-12.7%) | 1,040 | 158 | 15.2% (13.1%-17.4%) |
| Chronic renal failure | 35,644 | 2,262 | 6.3% (6.1%-6.6%) | 64,701 | 5,714 | 8.8% (8.6%-9.1%) |
| Chronic severe liver disease | 7,311 | 301 | 4.1% (3.7%-4.6%) | 10,654 | 580 | 5.4% (5.0%-5.9%) |
| Immunosuppressant use with RA | 2,257 | 292 | 12.9% (11.6%-14.3%) | 3,258 | 469 | 14.4% (13.2%-15.6%) |
| Immunosuppressant use without RA | 5,241 | 368 | 7.0% (6.3%-7.7%) | 7,573 | 668 | 8.8% (8.2%-9.5%) |
| Chronic disease present during baseline | ||||||
| Yes | 101,668 | 5,906 | 5.8% (5.7%-6.0%) | 160,139 | 12,620 | 7.9% (7.7%-8.0%) |
| No | 91,853 | 2,495 | 2.7% (2.6%-2.8%) | 129,140 | 4,734 | 3.7% (3.6%-3.8%) |
| Region | ||||||
| Western German states | 144,737 | 5,415 | 3.7% (3.6%-3.8%) | 220,669 | 11,098 | 5.0% (4.9%-5.1%) |
| Eastern German states | 48,274 | 2,974 | 6.2% (5.9%-6.4%) | 68,083 | 6,236 | 9.2% (8.9%-9.4%) |
RA = Rheumatoid arthritis; CI = confidence intervals:
*since number of vaccinated patients with stem cell transplantation were below 5, numbers are not shown here.